June 4A product called "Vimatrol®"(Generic name: anritriptanib) in a class of innovative medicinesFrom the Biomedical Valley of the New District, through prioritized review and approval.catchApproved for marketing by the State Drug Administration, for the treatment of adult and adolescent patients over the age of 12 with solid tumors carrying the NTRK fusion gene.
This is the first one approved for listing in Nanjing this year.Innovative medicinesVimetal® is the third new generation TRK inhibitor in the world. As a "cancer-free" anti-cancer drug, Vimetal® will bring new treatment options to more solid tumor patients.
This "Jiangbei-made" innovative drugs, the value of geometry
If I were to introduce this innovative drug in one sentence, it would go something like this:As long as the tumor carries a substance called"NTRK gene fusion" is a specific marker, regardless of where it grows in the lungs.In the mammary glands.neverthelessthyroid (gland)Glandular, Vimetal® can be precisely targeted and "locked".
To read about this breakthrough, you have to talk about the story behind it.
In our bodies, there is a family of genes called NTRK, which when fused with other genes, produce an abnormal TRK fusion protein that drives unlimited cell proliferation and eventually leads to tumors.
It is understood that NTRK gene fusion is widely present in more than 45 cancer types. Although the overall proportion is not high, China has a large population base, with about 15,000 new cases of tumors carrying NTRK fusion genes each year.these patientsinvariablyPoor prognosis, short survival, rapid disease progression and susceptibility to brain metastasis. Even trickier, first-generation TRK inhibitors often develop resistance after use, leaving treatment in limbo.
Vimetal® is here to break the ice for this very reason.
The relevant person in charge of the enterprise introduced this drug has three highlights: first, the efficacy is remarkable, the results of the registered clinical studies show that theTumor shrinkage or stability in patients with super 85% after treatment withSecondly, the drug has strong brain penetrating activity, and in clinical trials, it also achieved an objective remission rate of nearly 90% in patients with brain metastases; thirdly, the innovative cyclic molecular structure of Vimetal® can effectively avoid the problem of drug-resistant mutations.
"This is a broad-spectrum anticancer drug that is not limited to specific tumors." Dr. Yanchun Gong, co-founder, chairman, and CEO of Wickell Pharmaceuticals, said thatThe entire project started withClinical ApplicationApproved to Market Approval inMore than five years, all the teams and partners involved in R&D are moving forward at full speed, just to give more solid tumor patients earlier access to better quality treatments.
It is worth noting that this innovative drugIncluded in the "Pilot Program to Encourage Pediatric Antitumor Drug Development (Starlight Program)" by the State Drug Administration., clinical trial work for NTRK-resistant patients is also advancing rapidly.
From a new drug to a "drug valley".
Of course, Vimetal® is not alone in its creation.
If you cast your eyes to the new area of biomedical valley, you will find that under the Dragon King Mountain, the innovative drug reports frequently sound. In this "valley", a series of good drugs with memorable names have come out---
Precedent Pharmaceuticals'"First must be new."series, from injections to sublingual tablets, has snatched precious time for countless stroke patients to save their lives; Reindeer Bio's CAR-T cell therapyFocosol®The company has benefited hundreds of patients and attracted more than 40 overseas patients to China for treatment; Zhenxiang Pharmaceutical'sCiclosporin®, giving flu treatment a new domestic option ......
To date, the Valley has7 new drugs of the first class were approved for marketing. Last year, the city's three new drugs of a class, the Valley "contributed" two of them.It is important to know that in the field of biopharmaceuticals, new drug research and development usually has the "three laws of ten" - that is, it takes ten years, one billion dollars investment, ten percent success rate, a new drug is called the biopharmaceutical industry, "the crown jewels". The value is self-evident. The value is self-evident.
Not only these seven listed class I new drugs, in the Valley, there are many companies are targeting the clinical hard to gnaw the "hard core" launch of new drugs, the park will be a solid public technical service platform, complete upstream and downstream industry chain as well as accurate policy support, all the way to escort the growth of the park.
Today, more "seeds" are breaking ground in the park's laboratories.A number of new drugs pipeline ladder clear, full of strength, they may be the next "city's first", the next "global new".
The story of innovation has just turned a fascinating chapter at the bottom of Longwang Mountain.
